Active metabolite concentration of clopidogrel in patients taking different doses of aspirin: results of the interaction trial
Journal of Thrombosis and Haemostasis, ISSN: 1538-7836, Vol: 13, Issue: 3, Page: 347-352
2015
- 7Citations
- 41Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations7
- Citation Indexes7
- CrossRef4
- Captures41
- Readers41
- 41
Article Description
The CURRENT‐OASIS‐7 and PLATO trials suggest that the benefit of clopidogrel is influenced by the dose of aspirin. To explore a potential pharmacokinetic interaction between aspirin and clopidogrel, and determinants of clopidogrel active metabolite (AM) levels. In part 1, using a 2 × 2 factorial design, we randomized patients to clopidogrel 600 mg loading dose (LD) followed by 150 mg day −1 for 6 days and 75 mg day −1 thereafter, or clopidogrel 300 mg LD followed by 75 mg day −1 thereafter, and compared aspirin at 325 mg or 81 mg day −1. In part 2, patients were given a 600‐mg clopidogrel LD, and were randomly allocated to aspirin 325 mg or 81 mg day −1. We combine the data from the two parts. Blood samples were collected 1 h after administration of the study drug. We randomized 302 patients (mean age 60.4 ± 9.9 years). Clopidogrel AM levels were similar in patients randomized to aspirin 325 or 81 mg (geometric mean, 12.70 ng mL −1 ; 95% CI, 10.96–14.72 ng mL −1 ; and geometric mean, 12.55 ng mL −1 ; 95% CI, 10.80–14.58 ng mL −1 ; P = 0.91). Blood levels of clopidogrel were lower in CYP2C19*2 loss‐of‐function (LOF) carriers compared with non‐carriers (10.72 ng mL −1 ; 95% CI, 8.83–13.01 ng mL −1 ; and 15.21 ng mL −1 ; 95% CI, 13.30–17.40 ng mL −1, respectively; P = 0.003) whereas levels in gain of function carriers and non‐carriers were similar (13.31 ng mL −1 ; 95% CI, 11.53–15.35 ng mL −1 ; and 14.07 ng mL −1 ; 95% CI, 11.74–16.87 ng mL −1, respectively; P = 0.4). Independent baseline predictors of clopidogrel AM levels were LOF genotype, body mass index, diabetes, proton pump inhibitor use and creatinine clearance, but accounted for only 20% of the variability in levels. Aspirin dose does not predict clopidogrel AM levels 1 h post‐LD. Most of the variability in clopidogrel AM levels is not explained by patient characteristics or CYP2C19 metabolizer status.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1538783622086731; http://dx.doi.org/10.1111/jth.12829; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84923817295&origin=inward; https://clinicaltrials.gov/ct2/show/NCT01341964; http://www.ncbi.nlm.nih.gov/pubmed/25557828; https://linkinghub.elsevier.com/retrieve/pii/S1538783622086731; https://dx.doi.org/10.1111/jth.12829; https://onlinelibrary.wiley.com/doi/full/10.1111/jth.12829
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know